• 中国科技核心期刊
  • 中文科技期刊数据库刊源
  • 中国科技论文统计源期刊
  • 美国化学文摘社《化学文摘》刊源
Volume 34 Issue 3
May  2022
Turn off MathJax
Article Contents
Jin HE, Xiao-nan LU, Lu YAO, Jia ZHAO, Jing LI, Sheng-jun TA, Li-wen LIU. Quality of life and influencing factors in patients with hypertrophic cardiomyopathy[J]. Chinese Heart Journal, 2022, 34(3): 310-315. doi: 10.12125/j.chj.202112115
Citation: Jin HE, Xiao-nan LU, Lu YAO, Jia ZHAO, Jing LI, Sheng-jun TA, Li-wen LIU. Quality of life and influencing factors in patients with hypertrophic cardiomyopathy[J]. Chinese Heart Journal, 2022, 34(3): 310-315. doi: 10.12125/j.chj.202112115

Quality of life and influencing factors in patients with hypertrophic cardiomyopathy

doi: 10.12125/j.chj.202112115
  • Received Date: 2021-12-27
  • Rev Recd Date: 2022-02-13
  • Publish Date: 2022-05-26
  •   AIM   To investigate the quality of life (QOL) and its influencing factors in patients with hypertrophic cardiomyopathy (HCM), and provide evidence for improving the QOL of HCM patients.   METHODS   A total of 150 HCM patients were consecutively enrolled as subjects, and 150 healthy volunteers matched with age and sex were selected as control group. The QOL was measured with 36-item short-form Health Survey (SF-36), while clinical data and echocardiographic indicators were collected at the same time, and the influencing factors were further analyzed.   RESULTS  The score of every domain and component summary in SF-36 for HCM patients was lower than control group (P<0.05). Further analysis showed that age ≥65 years (β=−0.153, P<0.05), female gender (β=−0.130, P<0.05), New York Heart Association (NYHA) functional class Ⅲ~Ⅳ (β=−0.213, P<0.01), left ventricular outflow tract obstruction (LVOTO) (β=−0.418, P<0.01), comorbidity (β=−0.174, P<0.01), depression (β=−0.389, P<0.01) and anxiety (β=−0.176, P<0.05) were independent risk factors in HCM patients.   CONCLUSION  The QOL of HCM patients decrease in all dimensions, which is closely related to demographic factors, clinical features and emotional disorders. Therefore, in order to improve the QOL of HCM patients, health education and psychological intervention should be carried out according to the specific situation, in addition to relieving LVOTO and treating concomitant diseases.

     

  • loading
  • [1]
    Authors/Task Force members, Elliott PM, Anastasakis A, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the european society of cardiology (ESC)[J]. Eur Heart J, 2014, 35(39): 2733 – 2779. doi: 10.1093/eurheartj/ehu284
    [2]
    Semsarian C, Ingles J, Maron MS, et al. New perspectives on the prevalence of hypertrophic cardiomyopathy[J]. J Am Coll Cardiol, 2015, 65(12): 1249 – 1254. doi: 10.1016/j.jacc.2015.01.019
    [3]
    Maron BJ. Clinical course and management of hypertrophic cardiomyopathy[J]. N Engl J Med, 2018, 379(20): 1977. doi: 10.1056/NEJMc1812159
    [4]
    Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines.[J]. J Am Coll Cardiol, 2020, 76(25): 3022 – 3055. doi: 10.1016/j.jacc.2020.08.044
    [5]
    方积乾, 万崇华, 郝元涛. 与健康有关的生存质量的研究概况[J]. 中国康复医学杂志, 2000, 15(1): 39 – 43. doi: 10.3969/j.issn.1001-1242.2000.01.014
    [6]
    Cox S, O'Donoghue AC, McKenna WJ, et al. Health related quality of life and psychological wellbeing in patients with hypertrophic cardiomyopathy[J]. Heart, 1997, 78(2): 182 – 187. doi: 10.1136/hrt.78.2.182
    [7]
    Maron BJ, Maron MS, Rowin EJ. Perspectives on the overall risks of living with hypertrophic cardiomyopathy[J]. Circulation, 2017, 135(24): 2317 – 2319. doi: 10.1161/CIRCULATIONAHA.117.027738
    [8]
    Capota R, Militaru S, Ionescu AA, et al. Quality of life status determinants in hypertrophic cardiomyopathy as evaluated by the Kansas City Cardiomyopathy Questionnaire[J]. Health Qual Life Outcomes, 2020, 18(1): 351. doi: 10.1186/s12955-020-01604-9
    [9]
    李 鲁, 王红妹, 沈 毅. SF-36健康调查量表中文版的研制及其性能测试[J]. 中华预防医学杂志, 2002, 36(2): 109 – 113. doi: 10.3760/j:issn:0253-9624.2002.02.011
    [10]
    Lam CL, Tse EY, Gandek B, et al. The SF-36 summary scales were valid, reliable, and equivalent in a Chinese population[J]. J Clin Epidemiol, 2005, 58(8): 815 – 822. doi: 10.1016/j.jclinepi.2004.12.008
    [11]
    Lang RM, Badano LP, Mor-Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging[J]. Eur Heart J Cardiovasc Imaging, 2015, 16(3): 233 – 270. doi: 10.1093/ehjci/jev014
    [12]
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). i. conceptual framework and item selection[J]. Med Care, 1992, 30(6): 473 – 483. doi: 10.1097/00005650-199206000-00002
    [13]
    McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-item short-form health survey (sf-36): ii. psychometric and clinical tests of validity in measuring physical and mental health constructs[J]. Med Care, 1993, 31(3): 247 – 263. doi: 10.1097/00005650-199303000-00006
    [14]
    Holland R, Rechel B, Stepien K, et al. Patients' self-assessed functional status in heart failure by New York Heart Association class: a prognostic predictor of hospitalizations, quality of life and death[J]. J Card Fail, 2010, 16(2): 150 – 156. doi: 10.1016/j.cardfail.2009.08.010
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(4)

    Article views (73) PDF downloads(8) Cited by()
    Proportional views

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return